Scott CL - Search Results

1

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.

Bound NT, Vandenberg CJ, Kartikasari AER, Plebanski M, Scott CL. Bound NT, et al. Among authors: scott cl. Front Genet. 2022 Sep 9;13:886170. doi: 10.3389/fgene.2022.886170. eCollection 2022. Front Genet. 2022. PMID: 36159999 Free PMC article. Review.

2

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. van Delft MF, et al. Among authors: scott cl. Cancer Cell. 2006 Nov;10(5):389-99. doi: 10.1016/j.ccr.2006.08.027. Cancer Cell. 2006. PMID: 17097561 Free PMC article.

3

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.

Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, Roberts AW. Mason KD, et al. Among authors: scott cl. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17961-6. doi: 10.1073/pnas.0809957105. Epub 2008 Nov 11. Proc Natl Acad Sci U S A. 2008. PMID: 19004807 Free PMC article.

4

Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.

Campbell KJ, Bath ML, Turner ML, Vandenberg CJ, Bouillet P, Metcalf D, Scott CL, Cory S. Campbell KJ, et al. Among authors: scott cl. Blood. 2010 Oct 28;116(17):3197-207. doi: 10.1182/blood-2010-04-281071. Epub 2010 Jul 14. Blood. 2010. PMID: 20631380 Free PMC article.

5

Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death.

Michalak EM, Vandenberg CJ, Delbridge AR, Wu L, Scott CL, Adams JM, Strasser A. Michalak EM, et al. Among authors: scott cl. Genes Dev. 2010 Aug 1;24(15):1608-13. doi: 10.1101/gad.1940110. Genes Dev. 2010. PMID: 20679396 Free PMC article.

6

Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.

Happo L, Cragg MS, Phipson B, Haga JM, Jansen ES, Herold MJ, Dewson G, Michalak EM, Vandenberg CJ, Smyth GK, Strasser A, Cory S, Scott CL. Happo L, et al. Among authors: scott cl. Blood. 2010 Dec 9;116(24):5256-67. doi: 10.1182/blood-2010-04-280818. Epub 2010 Sep 9. Blood. 2010. PMID: 20829369 Free PMC article.

7

DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa.

Kerr JB, Hutt KJ, Michalak EM, Cook M, Vandenberg CJ, Liew SH, Bouillet P, Mills A, Scott CL, Findlay JK, Strasser A. Kerr JB, et al. Among authors: scott cl. Mol Cell. 2012 Nov 9;48(3):343-52. doi: 10.1016/j.molcel.2012.08.017. Epub 2012 Sep 20. Mol Cell. 2012. PMID: 23000175 Free PMC article.

8

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS); deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL. Kondrashova O, et al. Among authors: scott cl. Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z. Nat Commun. 2018. PMID: 30266954 Free PMC article.

9

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.

Sanij E, Hannan KM, Xuan J, Yan S, Ahern JE, Trigos AS, Brajanovski N, Son J, Chan KT, Kondrashova O, Lieschke E, Wakefield MJ, Frank D, Ellis S, Cullinane C, Kang J, Poortinga G, Nag P, Deans AJ, Khanna KK, Mileshkin L, McArthur GA, Soong J, Berns EMJJ, Hannan RD, Scott CL, Sheppard KE, Pearson RB. Sanij E, et al. Among authors: scott cl. Nat Commun. 2020 May 26;11(1):2641. doi: 10.1038/s41467-020-16393-4. Nat Commun. 2020. PMID: 32457376 Free PMC article.

10

CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors.

Xu Z, Vandenberg CJ, Lieschke E, Di Rago L, Scott CL, Majewski IJ. Xu Z, et al. Among authors: scott cl. Mol Cancer Res. 2021 Aug;19(8):1350-1360. doi: 10.1158/1541-7786.MCR-20-0791. Epub 2021 Apr 16. Mol Cancer Res. 2021. PMID: 33863812

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

266 results

Search Page